PACSIN2 polymorphism influences TPMT activity and mercaptopurine-related gastrointestinal toxicity

Human Molecular Genetics

Volumn 21, Issue 21, 2012, Pages 4793-4804

  Stocco, Gabriele ^a,b   Yang, Wenjian ^a   Crews, Kristine R ^a   Thierfelder, William E ^a   Decorti, Giuliana ^b   Londero, Margherita ^c   Franca, Raffaella ^c   Rabusin, Marco ^c   Valsecchi, Maria Grazia ^d   Pei, Deqing ^a   Cheng, Cheng ^a   Paugh, Steven W ^a   Ramsey, Laura B ^a   Diouf, Barthelemy ^a   Mccorkle, Joseph Robert ^a   Jones, Terreia S ^e   Pui, Ching Hon ^a   Relling, Mary V ^a,e   Evans, William E ^a,e  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TRIESTE   (Italy)

^c INSTITUTE FOR MATERNAL AND CHILD HEALTH IRCCS BURLO GAROFOLO   (Italy)

^d UNIVERSITY OF MILANO BICOCCA   (Italy)

^e UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FOLINIC ACID; MERCAPTOPURINE; MESSENGER RNA; METHOTREXATE; ORGANIC ANION TRANSPORTER 2; THIOPURINE METHYLTRANSFERASE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CHILDHOOD LEUKEMIA; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIARRHEA; DRUG MEGADOSE; ENZYME ACTIVITY; GASTROINTESTINAL TOXICITY; GENE; GENE EXPRESSION; GENE SILENCING; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HUMAN; HUMAN CELL; INCIDENCE; LEUKEMIA CELL; LIVER TOXICITY; MUCOSA INFLAMMATION; MULTIVARIATE ANALYSIS; NUCLEOTIDE SEQUENCE; PANCREAS DISEASE; PRIORITY JOURNAL; PROTEIN KINASE C AND CASEIN KINASE SUBSTRATE IN NEURONS 2 GENE; SINGLE NUCLEOTIDE POLYMORPHISM; VOMITING;

6-MERCAPTOPURINE; ADAPTOR PROTEINS, SIGNAL TRANSDUCING; CELL LINE, TUMOR; CHILD; CHILD, PRESCHOOL; DRUG TOXICITY; FEMALE; GASTROINTESTINAL TRACT; GENE EXPRESSION; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HAPMAP PROJECT; HUMANS; MALE; METHYLTRANSFERASES; POLYMORPHISM, SINGLE NUCLEOTIDE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 84867788966     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/dds302     Document Type: Article

References (42)

1. Pui, C.H., Carroll, W.L., Meshinchi, S. and Arceci, R.J. (2012) Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J. Clin. Oncol., 29, 551-565.
2. Pui, C.H. and Evans, W.E. (2006) Treatment of acute lymphoblastic leukemia. N. Engl. J. Med., 354, 166-178.
3. Paugh, S.W., Stocco, G., McCorkle, J.R., Diouf, B., Crews, K.R. and Evans, W.E. (2011) Cancer pharmacogenomics. Clin. Pharmacol. Ther., 90, 461-466.
4. Wang, L. and Weinshilboum, R. (2006) Thiopurine S-methyltransferase pharmacogenetics: insights, challenges and future directions. Oncogene, 25, 1629-1638.
5. Krynetski, E. and Evans, W.E. (2003) Drug methylation in cancer therapy: lessons from the TPMT polymorphism. Oncogene, 22, 7403-7413.
6. Relling, M.V., Gardner, E.E., Sandborn, W.J., Schmiegelow, K., Pui, C.H., Yee, S.W., Stein, C.M., Carrillo, M., Evans, W.E. and Klein, T.E. (2011) Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin. Pharmacol. Ther., 89, 387-391.
7. Relling, M.V., Hancock, M.L., Rivera, G.K., Sandlund, J.T., Ribeiro, R.C., Krynetski, E.Y., Pui, C.H. and Evans, W.E. (1999) Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J. Natl. Cancer. Inst., 91, 2001-2008.
8. Trevino, L.R., Shimasaki, N., Yang, W., Panetta, J.C., Cheng, C., Pei, D., Chan, D., Sparreboom, A., Giacomini, K.M., Pui, C.H. et al. (2009) Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. J. Clin. Oncol., 27, 5972-5978.
9. Peters, E.J., Kraja, A.T., Lin, S.J., Yen-Revollo, J.L., Marsh, S., Province, M.A. and McLeod, H.L. (2009) Association of thymidylate synthase variants with 5-fluorouracil cytotoxicity. Pharmacogenet. Genomics, 19, 399-401.
10. Wheeler, H.E. and Dolan, M.E. (2012) Lymphoblastoid cell lines in pharmacogenomic discovery and clinical translation. Pharmacogenomics, 13, 55-70.
11. Jones, T.S., Yang, W., Evans, W.E. and Relling, M.V. (2007) Using HapMap tools in pharmacogenomic discovery: the thiopurine methyltransferase polymorphism. Clin. Pharmacol. Ther., 81, 729-734.
12. Gamazon, E.R., Huang, R.S., Cox, N.J. and Dolan, M.E. (2010) Chemotherapeutic drug susceptibility associated SNPs are enriched in expression quantitative trait loci. Proc. Natl. Acad. Sci. USA, 107, 9287-9292.
13. Nicolae, D.L., Gamazon, E., Zhang, W., Duan, S., Dolan, M.E. and Cox, N.J. (2010) Trait-associated SNPs are more likely to be eQTLs: annotation to enhance discovery from GWAS. PLoS Genet., 6, e1000888.
14. Kishi, S., Cheng, C., French, D., Pei, D., Das, S., Cook, E.H., Hijiya, N., Rizzari, C., Rosner, G.L., Frudakis, T. et al. (2007) Ancestry and pharmacogenetics of antileukemic drug toxicity. Blood, 109, 4151-4157.
15. Tai, H.L., Fessing, M.Y., Bonten, E.J., Yanishevsky, Y., d'Azzo, A., Krynetski, E.Y. and Evans, W.E. (1999) Enhanced proteasomal degradation of mutant human thiopurine S-methyltransferase (TPMT) in mammalian cells: mechanism for TPMT protein deficiency inherited by TPMT*2, TPMT*3A, TPMT*3B or TPMT*3C. Pharmacogenetics, 9, 641-650.
16. Stanulla, M., Schaeffeler, E., Flohr, T., Cario, G., Schrauder, A., Zimmermann, M., Welte, K., Ludwig, W.D., Bartram, C.R., Zanger, U.M. et al. (2005) Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia. J.A.M.A., 293, 1485-1489.
17. Kessels, M.M. and Qualmann, B. (2004) The syndapin protein family: linking membrane trafficking with the cytoskeleton. J. Cell Sci., 117, 3077-3086.
18. Modregger, J., Ritter, B., Witter, B., Paulsson, M. and Plomann, M. (2000) All three PACSIN isoforms bind to endocytic proteins and inhibit endocytosis. J. Cell Sci., 113(Pt 24), 4511-4521.
19. Meng, H., Tian, L., Zhou, J., Li, Z., Jiao, X., Li, W.W., Plomann, M., Xu, Z., Lisanti, M.P., Wang, C. et al. (2011) PACSIN 2 represses cellular migration through direct association with cyclin D1 but not its alternate splice form cyclin D1b. Cell Cycle, 10, 73-81.
20. Szyniarowski, P., Corcelle-Termeau, E., Farkas, T., Hoyer-Hansen, M., Nylandsted, J., Kallunki, T. and Jaattela, M. (2011) A comprehensive siRNA screen for kinases that suppress macroautophagy in optimal growth conditions. Autophagy, 7, 892-903.
21. Qualmann, B. and Kelly, R.B. (2000) Syndapin isoforms participate in receptor-mediated endocytosis and actin organization. J. Cell. Biol., 148, 1047-1062.
22. Wang, Q., Navarro, M.V., Peng, G., Molinelli, E., Goh, S.L., Judson, B.L., Rajashankar, K.R. and Sondermann, H. (2009) Molecular mechanism of membrane constriction and tubulation mediated by the F-BAR protein Pacsin/Syndapin. Proc. Natl. Acad. Sci. U. S. A., 106, 12700-12705.
23. Takahashi, Y., Coppola, D., Matsushita, N., Cualing, H.D., Sun, M., Sato, Y., Liang, C., Jung, J.U., Cheng, J.Q., Mule, J.J. et al. (2007) Bif-1 interacts with Beclin 1 through UVRAG and regulates autophagy and tumorigenesis. Nat. Cell. Biol., 9, 1142-1151.
24. Takahashi, Y., Meyerkord, C.L., Hori, T., Runkle, K., Fox, T.E., Kester, M., Loughran, T.P. and Wang, H.G. (2011) Bif-1 regulates Atg9 trafficking by mediating the fission of Golgi membranes during autophagy. Autophagy, 7, 61-73.
25. Behrends, C., Sowa, M.E., Gygi, S.P. and Harper, J.W. (2010) Network organization of the human autophagy system. Nature, 466, 68-76.
26. Li, F., Wang, L., Burgess, R.J. and Weinshilboum, R.M. (2008) Thiopurine S-methyltransferase pharmacogenetics: autophagy as a mechanism for variant allozyme degradation. Pharmacogenet. Genomics, 18, 1083-1094.
27. Raney, B.J., Cline, M.S., Rosenbloom, K.R., Dreszer, T.R., Learned, K., Barber, G.P., Meyer, L.R., Sloan, C.A., Malladi, V.S., Roskin, K.M. et al. (2011) ENCODE whole-genome data in the UCSC genome browser (2011 update). Nucleic Acids Res., 39, D871-D875.
28. Rosenbloom, K.R., Dreszer, T.R., Pheasant, M., Barber, G.P., Meyer, L.R., Pohl, A., Raney, B.J., Wang, T., Hinrichs, A.S., Zweig, A.S. et al. (2010) ENCODE whole-genome data in the UCSC Genome Browser. Nucleic Acids Res., 38, D620-D625.
29. Kent, W.J., Sugnet, C.W., Furey, T.S., Roskin, K.M., Pringle, T.H., Zahler, A.M. and Haussler, D. (2002) The human genome browser at UCSC. Genome Res., 12, 996-1006.
30. McLeod, H.L., Coulthard, S., Thomas, A.E., Pritchard, S.C., King, D.J., Richards, S.M., Eden, O.B., Hall, A.G. and Gibson, B.E. (1999) Analysis of thiopurine methyltransferase variant alleles in childhood acute lymphoblastic leukaemia. Br. J. Haematol, 105, 696-700.
31. Roberts, R.L., Gearry, R.B., Bland, M.V., Sies, C.W., George, P.M., Burt, M., Marinaki, A.M., Arenas, M., Barclay, M.L. and Kennedy, M.A. (2008) Trinucleotide repeat variants in the promoter of the thiopurine S-methyltransferase gene of patients exhibiting ultra-high enzyme activity. Pharmacogenet. Genomics, 18, 434-438.
32. de Kreuk, B.J., Nethe, M., Fernandez-Borja, M., Anthony, E.C., Hensbergen, P.J., Deelder, A.M., Plomann, M. and Hordijk, P.L. (2011) The F-BAR domain protein PACSIN2 associates with Rac1 and regulates cell spreading and migration. J. Cell Sci., 124, 2375-2388.
33. Tiede, I., Fritz, G., Strand, S., Poppe, D., Dvorsky, R., Strand, D., Lehr, H.A., Wirtz, S., Becker, C., Atreya, R. et al. (2003) CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J. Clin. Invest., 111, 1133-1145.
34. Stocco, G., Cheok, M.H., Crews, K.R., Dervieux, T., French, D., Pei, D., Yang, W., Cheng, C., Pui, C.H., Relling, M.V. et al. (2009) Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia. Clin. Pharmacol. Ther., 85, 164-172.
35. McLeod, H.L., Lin, J.S., Scott, E.P., Pui, C.H. and Evans, W.E. (1994) Thiopurine methyltransferase activity in American white subjects and black subjects. Clin. Pharmacol. Ther., 55, 15-20.
36. Pui, C.H., Pei, D., Sandlund, J.T., Ribeiro, R.C., Rubnitz, J.E., Raimondi, S.C., Onciu, M., Campana, D., Kun, L.E., Jeha, S. et al. (2010) Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia. Leukemia, 24, 371-382.
37. Pui, C.H., Campana, D., Pei, D., Bowman, W.P., Sandlund, J.T., Kaste, S.C., Ribeiro, R.C., Rubnitz, J.E., Raimondi, S.C., Onciu, M. et al. (2009) Treating childhood acute lymphoblastic leukemia without cranial irradiation. N. Engl. J. Med., 360, 2730-2741.
38. Pui, C.H., Sandlund, J.T., Pei, D., Campana, D., Rivera, G.K., Ribeiro, R.C., Rubnitz, J.E., Razzouk, B.I., Howard, S.C., Hudson, M.M. et al. (2004) Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. Blood, 104, 2690-2696.
39. Schrappe, M., Valsecchi, M.G., Bartram, C.R., Schrauder, A., Panzer-Grumayer, R., Moricke, A., Parasole, R., Zimmermann, M., Dworzak, M., Buldini, B. et al. (2011) Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study. Blood, 118, 2077-2084.
40. Holm, S. (1979) A simple sequentially rejective multiple test procedure. Scand. J. Stat., 6, 65-70.
41. Jain, N., Thatte, J., Braciale, T., Ley, K., O'Connell, M. and Lee, J.K. (2003) Local-pooled-error test for identifying differentially expressed genes with a small number of replicated microarrays. Bioinformatics, 19, 1945-1951.
42. Benjamini, Y. and Hochberg, Y. (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. Series B, 57, 289-300.